Cancer Lab · DeCure for X
DeCure's autonomous Cancer AI scientist is researching a drug-repurposing hypothesis for pulmonary blastoma — screening already-approved drugs against its 46-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
No approved-drug candidate for pulmonary blastoma is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
NRAS proto-oncogene, GTPase (NRAS) — NRAS is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
RCSB Protein Data Bank · entry 6ZIO · 1.55 Å · ligand GUANOSINE-5'-DIPHOSPHATE (GDP). Experimental structure, not a prediction.
Pulmonary blastoma is one of the least common primary malignant tumours of the lung. A 1974 case report described a tumour suspected at surgery that proved on histological examination to be a pulmonary blastoma. Three cases reported in 1988 described radiological, cytological, and histopathological features in detail. A 1990 journal article by Frederic B. Askin appeared in the American Journal of Clinical Pathology. A 1981 case of a four-year-old girl with pulmonary blastoma was diagnosed by two independent pathologists; the tumour’s histological demarcation was described as difficult and contested.
Because of the malignancy, a combined surgical-cytostatic-radiological therapy was decided upon, which the authors noted had not yet been done in that way. The patient was symptom-free for six months but then died from a brain metastasis. No other survival data, response rates, or sample sizes beyond these individual cases are reported in these abstracts. No drug is named in any of the abstracts.
What is still missing is any systematic trial, any patient stratification, any funding for prospective research, and any evidence that any drug has been tested against pulmonary blastoma in any number of patients.
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Abstract<b>Rao, K. M., Gupta, R. P., Das, P. B., John, S., and Walter, A. (1974).</b><i>Thorax</i>, <b>29</b>, 138-141. <b>Pulmonary blastoma.</b> A case report of a pulmonary blastoma is presented. A tumour was suspected at surgery and on histological examination this proved to be a pulmonary blastoma. A short review of the histogenesis and methods of treatment is given.
https://doi.org/10.1136/thx.29.1.138AbstractPulmonary blastoma is one of the least common primary malignant tumors of the lung. There is considerable controversy as to its exact histogenesis; it is uncertain if it arises from a single cell or if it is a mixed tumor arising from two different cell lines. We report three patients with pulmonary blastomas, describing in detail their radiological, cytological, and histopathological features.
https://doi.org/10.1177/084653718803900212AbstractJournal Article Pulmonary Blastoma Get access Frederic B. Askin, M.D. Frederic B. Askin, M.D. Professor of Pathology Director of Surgical Pathology University of North Carolina Hospitals University of North Carolina Medical School Chapel Hill, North Carolina Search for other works by this author on: Oxford Academic Google Scholar American Journal of Clinical Pathology, Volume 93, Issue 2, 1 February 1990, Pages 294–295, https://doi.org/10.1093/ajcp/93.2.294 Published: 01 February 1990
https://doi.org/10.1093/ajcp/93.2.294AbstractA case of a pulmonary blastoma is presented. The tumor's histological demarcation is difficult and contested. The diagnosis was delivered by two independent pathologists. Because of the malignancy of the tumor we decided on a combined surgical-cytostatic-radiological therapy, which has not yet been done in this way. The patient was symptom-free for 6 months, she then died however, from a brain metastasis.
https://doi.org/10.1055/s-2008-1063118Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
